沙立度胺联合MP化疗方案治疗多发性骨髓瘤23例  

Clinical efficacy of thalidomide with melphalan and prednison in the treatment of 23 cases multiple myeloma

作　　者：郑翠苹[1] 张卫平[1] 徐杰[1] 

机构地区：[1]温州市第二人民医院血液化疗科,浙江温州325000

出　　处：《临床血液学杂志》2005年第5期277-278,共2页Journal of Clinical Hematology

摘　　要：目的:观察沙立度胺联合MP方案治疗多发性骨髓瘤的疗效及其不良反应。方法:确诊的多发性骨髓瘤患者23例。沙立度胺MP方案:沙立度胺自MP方案开始持续给药,每晚睡前口服,剂量从每天100mg开始,每周日剂量递增50mg,至患者不能耐受或最高至每日400mg;MP方案每月1个疗程。结果:部分缓解16例(69.6%),进步4例(17.4%),总有效率为87.0%(20/23)。有效的患者中10例在4周内起效,沙立度胺每天100～400mg,中位剂量每天225mg。常见的不良反应为皮疹、便秘、嗜睡、乏力、头昏、水肿等。结论:沙立度胺加MP方案治疗多发性骨髓瘤不良反应少,耐受性好,且反应率可能提高。Objective：To report the preliminary result of therapy with thalidomide in 23 cases of multiple myeloma（MM） patients. Method：The initial dose of thalidomide was 100 mg/d, then increased 50 mg/d to 400 mg/d every week until the patient＇s maximal tolerance. Chemotherapy with melphalan 0. 1 mg/kg daily and oral predni son 1.0 mg/kg daily for seven clays was accompanied in all patients. Result： Among the 23 patients 16 achieved partial remission （PR）, 4 improved and 3 had no effect. Conclusion： Thalidomide can be used in the treatment of MM. Side effects was tolerable.

关 键 词：多发性骨髓瘤 沙立度胺 

分 类 号：R733.3[医药卫生—肿瘤]